Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

Revisiting History of Treatment of Attention Deficit Hyperactivity Disorder : Pharmacologic Approach

주의력결핍 과잉행동장애 치료의 역사적 재조명 : 약물치료적 접근

  • Bahn, Geon Ho (Department of Psychiatry, School of Medicine, Kyung Hee University) ;
  • Hong, Min Ha (Department of Psychiatry, Dankook University Hospital) ;
  • Lee, Yeon Jung (Department of Psychiatry, Kyung Hee University Hospital) ;
  • Han, Ju Hee (Department of Psychiatry, Kyung Hee University Hospital) ;
  • Oh, Soo Hyun (Department of Life Sciences, Ewha Womans University)
  • 반건호 (경희대학교 의학전문대학원 정신건강의학교실) ;
  • 홍민하 (단국대학교병원 정신건강의학과) ;
  • 이연정 (경희대학교병원 정신건강의학과) ;
  • 한주희 (경희대학교병원 정신건강의학과) ;
  • 오수현 (이화여자대학교 생명과학과)
  • Received : 2014.03.17
  • Accepted : 2014.04.02
  • Published : 2014.05.28
Download PDF
⟨ Previous Next ⟩

Abstract

Besides from medical data, the patients who were previously called as attention disorder, mental instability, moral imbeciles, or moral defectives, can also be identified by exploring literatures and historical figures. In the past, as we can notice from the titles, they were recognized as a 'moral defect group'. And rather than treating them, separation from the society was the main solution. After the endemic encephalitis from 1917 to late 1920s, however, many survivors suffered from behavioral problems similar to those of the previous 'moral defect group' and studies on the relationship between brain damage and behavior problems were started henceforth. After being known as the 'minimal brain dysfunction', it was developed into the current attention-deficit/hyperactivity disorder. While the disease concept changed and developed over time, after numerous trials and errors, treatment medication starting from central nervous system stimulants such as amphetamine and methylphenidate is used for treatment in children and adult patients with ADHD, and most recently non-stimulants such as atomoxetine has become the one of the first line treatment options. Although we went through a thorough verification process of the safety and efficacy of the medication by contemplating the historical development process, we believe that adjustment is needed for remaining concerns on medication abuse and slight differences in disease paradigm and therapeutic philosophy depending on cultures.

Keywords

References

  1. Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, et al. Trends in the parent-report of health care provider- diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry 2014;53:34-46. https://doi.org/10.1016/j.jaac.2013.09.001
  2. Dalsgaard S, Nielsen HS, Simonsen M. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study. J Child Adolesc Psychopharmacol 2013;23:432-439. https://doi.org/10.1089/cap.2012.0111
  3. Iversen LL. Speed, Ecstasy, Ritalin: the Science of Amphetamines. Oxford: Oxford University Press;2008.
  4. Walkup JT, Stossel L, Rendleman R. Beyond rising rates: personalized medicine and public health approaches to the diagnosis and treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2014;53:14-16. https://doi.org/10.1016/j.jaac.2013.10.008
  5. Bahn GH, Bae J, Moon S, Min J. ADHD, new developed or newly found: historical review. Korean Acad Child Adolesc Psychiatry 2011; 22:57-66. https://doi.org/10.5765/JKACAP.2011.22.2.057
  6. American Psychiatric Association. Diagnostic and Statistical Manual: Mental Disorders. Washington, DC: American Psychiatric Association; 1952.
  7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R. 3rd ed., Rev. Washington, DC: American Psychiatric Association;1987.
  8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association;2013.
  9. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother 2014;48:209-225. https://doi.org/10.1177/1060028013510699
  10. Christensen L, Sasané R, Hodgkins P, Harley C, Tetali S. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 2010;26:977-989. https://doi.org/10.1185/03007991003673617
  11. Bahn GH, Hong MH, Lee YJ. The prince who gave up the throne, was he ADHD? Poster presented at the 4th World Congress on ADHD, 6-9 June 2013. Milan: World Congress on ADHD;2013.
  12. Lange KW, Reichl S, Lange KM, Tucha L, Tucha O. The history of attention deficit hyperactivity disorder. Atten Defic Hyperact Disord 2010;2:241-255. https://doi.org/10.1007/s12402-010-0045-8
  13. Taylor E. Antecedents of ADHD: a historical account of diagnostic concepts. Atten Defic Hyperact Disord 2011;3:69-75. https://doi.org/10.1007/s12402-010-0051-x
  14. Thome J, Jacobs KA. Attention deficit hyperactivity disorder (ADHD) in a 19th century children's book. Eur Psychiatry 2004;19:303-306. https://doi.org/10.1016/j.eurpsy.2004.05.004
  15. Kropotov J. Quantitative EEG, Event-Related Potentials and Neurotherapy. Waltham: Academic Press;2010.
  16. Teive HA, Zavala JA, Munhoz RP, Lara DR, Lima P, Palmini A. Attention deficit hyperactivity disorder and the behavior of "Che" Guevara. J Clin Neurosci 2009;16:1136-1138. https://doi.org/10.1016/j.jocn.2008.12.003
  17. Anderson JL. Che Guevara: A Revolutionary Life. New York: Grove Press;1997.
  18. Castro F, Ramonet I. Fidel Castro My Life: A Spoken Autobiography. New York: Scribner;2009.
  19. Barkley RA, Peters H. The earliest reference to ADHD in the medical literature? Melchior Adam Weikard's description in 1775 of "attention deficit" (Mangel der Aufmerksamkeit, Attentio Volubilis). J Atten Disord 2012;16:623-630. https://doi.org/10.1177/1087054711432309
  20. Crichton A. An inquiry into the nature and origin of mental derangement: comprehending a concise system of the physiology and pathology of the human mind and a history of the passions and their effects. London: Printed for T. Cadell, junior, and W. Davies;1798. p.271-278.
  21. Clouston TS. Stages of over-excitability, hypersensitiveness, and mental explosiveness in children and their treatment by the bromides. Scott Med Surg J 1899;4:481-490.
  22. Still GF. Some abnormal psychical conditions in children: the Goulstonian lectures. Lancet 1902;1:1008-1012.
  23. Still GF. Some abnormal psychical conditions in children: the Goulstonian lectures. Lancet 1902;1:1077-1082.
  24. Still GF. Some abnormal psychical conditions in children: the Goulstonian lectures. Lancet 1902;1:1163-1168.
  25. Bader M, Hadjikhani N. The concept of instability: a French perspective on the concept of ADHD. Atten Defic Hyperact Disord 2014; 6:11-17. https://doi.org/10.1007/s12402-013-0121-y
  26. Bourneville DM. Imbecillite legere, instabilite mentale avec perversion des instincts et impulsions genitales (Kleptomanie, onanisme, sodomie, syphillis). In: Bourneville DM, editor. Recherches cliniques et therapeutiques sur l'épilepsie et l'idiotie pour 1888. Paris: Publications du Progres Medical, E. Lecrosnier et Babe;1889.
  27. Boulanger C. Contribution a l'etude de l'instabilite mentale. These pour le Doctorat en Medecine. Paris: Imprimerie de la Faculte de Medecine; 1892.
  28. Bourneville DM. Lettre aux membres de la 3eme Commission du Conseil General de la Seine sur la creation de classes speciales pour les enfants arrieres, Bicetre, imprimerie des enfants (Lettre datee du 10 decembre 1896). Paris: Bicetre, Imprimerie des enfants;1897.
  29. Philippe J, Paul-Boncour G. Les anomalies mentales chez les ecoliers. Paris: F. Alcan;1905.
  30. Binet A, Simon T. Les enfants anormaux. Guide pour l'admission dans les classes de perfectionnement. Paris: Colin;1907.
  31. Lee BW. Historical essay on psychoanalysis in France. Psychoanalysis 2001;12:84-97.
  32. Tredgold AF. Mental Deficiency (Amentia). New York: Wood;1908.
  33. Kahn E, Cohen LH. Organic drivenness a brain-stem syndrome and an experience. Ne Eng J Med 1934;210:748-756. https://doi.org/10.1056/NEJM193404052101405
  34. Rafalovich A. The conceptual history of attention deficit hyperactivity disorder: idiocy, imbecility, encephalitis and the child deviant, 1877-1929. Deviant Behav 2001;22:93-115. https://doi.org/10.1080/016396201750065009
  35. Ross DM, Ross SA. Hyperactivity: Research, Theory, and Action. New York: Wiley;1976. p.15.
  36. Levin S. Electroencephalogram in postencephalitic behavior disorder and postencephalitic parkinsonism. Am J Psychiatry 1948;105: 439-442. https://doi.org/10.1176/ajp.105.6.439
  37. Barkley RA. Attention-Deficit Hyperactivity Disorder: a Handbook for Diagnosis and Treatment. 3rd ed. New York: Guilford Press;2006.
  38. Lewin PM. Restlessness in children. Arch Neurol Psych 1938;39: 764-770. https://doi.org/10.1001/archneurpsyc.1938.02270040120006
  39. Strauss AA, Lehtinen LE, Kephart NC. Psychopathology and Education of the Brain-Injured Child. New York: Grune & Stratton;1947.
  40. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. 6th ed. Geneva: World Heath Organization;1949.
  41. Sandberg S. Hyperactivity and Attention Disorders of Childhood. 2nd ed. Cambridge: Cambridge University Press;2002.
  42. Göllnitz G. The hyperkinetic child. In: Gittelman M, editor. Strategic Interventions for Hyperactive Children. Armonk: M.E. Sharpe; 1981. p.80-96.
  43. Gillberg IC, Gillberg C. Children with deficits in attention, motor control and perception (DAMP): need for specialist treatment. Acta Paediatr Scand 1988;77:450-451. https://doi.org/10.1111/j.1651-2227.1988.tb10678.x
  44. Yoon HB. A review study on Japan's assistance act for develop mental disabilities. J Spec Child Educ 2012;14:295-311. https://doi.org/10.21075/kacsn.2012.14.4.295
  45. Strohl MP. Bradley's Benzedrine studies on children with behavioral disorders. Yale J Biol Med 2011;84:27-33.
  46. Bradley C. The Behavior of Children Reveiving Benzedrine. Am J Psychiatry 1937;94:577-585. https://doi.org/10.1176/ajp.94.3.577
  47. Cullen PVH. A Stranger in Blood: the Case Files on Dr John Bodkin Adams. London: Elliott & Thompson;2006.
  48. Rasmussen N. On Speed: the Many Lives of Amphetamine. New York: New York University Press;2008.
  49. Alles GA. The comparative physiological action of phenylethanolamine. J Pharmacol Exp Ther 1928;32:121-128.
  50. Natlianson MH. The central action of beta-aminopropyl- benzene (Benzedrine). JAMA 1937;108:528-531. https://doi.org/10.1001/jama.1937.02780070012004
  51. Bahnsen E, Thesleff JH. The subjective effect of beta-phenylisopropylaminsulfate on normal adults. Acta Med Scand 1938;97:89-131.
  52. Bradley C, Margaret B. Amphetamine (benzedrine) therapy of children's behavior disorders. Am J Orthopsychiatr 1941;11;92. https://doi.org/10.1111/j.1939-0025.1941.tb05781.x
  53. Denhoff E, Laufer MW, Solomons G. Hyperkinetic impulse disorder in children's behavior problems. Psychosom Med 1957;19:38-49. https://doi.org/10.1097/00006842-195701000-00005
  54. Rosenfeld GB, Bradley C. Childhood behavior sequelae of asphyxia in infancy, with special reference to pertussis and asphyxia neonatorum. Pediatrics 1948;2:74-84.
  55. Frosch J, Wortis SB. A contribution to the nosology of the impulse disorders. Am J Psychiatry 1954;111:132-138. https://doi.org/10.1176/ajp.111.2.132
  56. Gastaut H. Combined photic and metrazol activation of the brain. Electroencephalogr Clin Neurophysiol 1950;2:249-261. https://doi.org/10.1016/0013-4694(50)90056-3
  57. Singh I. Not just naughty: 50 years of stimulant drug advertising. In: Tone A, Watkins ES, editors. Medicating Modern America: Prescription Drugs in History. New York: New York University Press;2007.
  58. Weiss B, Laties VG. Enhancement of human performance by caffeine and the amphetamines. Pharmacol Rev 1962;14:1-36.
  59. Leonard BE, McCartan D, White J, King DJ. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 2004;19:151-180. https://doi.org/10.1002/hup.579
  60. Stein D. Ritalin Is Not the Answer: a Drug-Free, Practical Program For Children Diagnosed with ADD or ADHD. San Francisco: Jossey- Bass;1999.
  61. Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007;369:1047-1053. https://doi.org/10.1016/S0140-6736(07)60464-4
  62. Ichikawa H. History of ADHD in Japan. Program and abstracts at the 2nd Asia Congress on ADHD, 8 March 2014. Tokyo: Asia Congress on ADHD;2014. p.28.
  63. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005;293:1995-2002. https://doi.org/10.1001/jama.293.16.1995
  64. Hong MH. The Incidence of ADHD and Pharmacotherapy in Korea: Nationwide Study from 2007 to 2011. Oral presentation at the 2nd Asia Congress on ADHD, 8 March 2014. Tokyo: Asia Congress on ADHD;2014.
  65. Preti A. Tomoxetine (Eli Lilly & Co). Curr Opin Investig Drugs 2002; 3:272-277.
  66. Faraone SV, Biederman J, Spencer T, Michelson D, Adler L, Reimherr F, et al. Atomoxetine and stroop task performance in adult attention- deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005;15:664-670. https://doi.org/10.1089/cap.2005.15.664